182 related articles for article (PubMed ID: 36556957)
1. A Reduction of Calcineurin Inhibitors May Improve Survival in Patients with De Novo Colorectal Cancer after Liver Transplantation.
Ossami Saidy RR; Wegener E; Uluk D; Dittrich L; Schöning W; Lurje G; Öllinger R; Modest DP; Tacke F; Haase O; Pratschke J; Eurich D
Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556957
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive Treatment With mTOR Inhibitors for Malignancies After Liver Transplantation: Long-Term Survival Retrospective Analysis.
Tejedor-Tejada J; Alonso-Martín C; Almohalla-Álvarez C; Valenzuela EF; Muñoz RN; Delgado LS; Martín CM; Sánchez-Martín F; García-Pajares F; Sánchez-Antolín G
Transplant Proc; 2020 Jun; 52(5):1507-1510. PubMed ID: 32213292
[TBL] [Abstract][Full Text] [Related]
3. Conversion from Calcineurin Inhibitor-Based Immunosuppression to Mycophenolate Mofetil in Monotherapy Reduces Risk of De Novo Malignancies After Liver Transplantation.
Aguiar D; Martínez-Urbistondo D; D'Avola D; Iñarrairaegui M; Pardo F; Rotellar F; Sangro B; Quiroga J; Herrero JI
Ann Transplant; 2017 Mar; 22():141-147. PubMed ID: 28302995
[TBL] [Abstract][Full Text] [Related]
4. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients.
Wimmer CD; Angele MK; Schwarz B; Pratschke S; Rentsch M; Khandoga A; Guba M; Jauch KW; Bruns C; Graeb C
Transpl Int; 2013 Oct; 26(10):999-1006. PubMed ID: 23952102
[TBL] [Abstract][Full Text] [Related]
5. 'De novo' and 'recurrent' autoimmune hepatitis after liver transplantation: A comprehensive review.
Kerkar N; Yanni G
J Autoimmun; 2016 Jan; 66():17-24. PubMed ID: 26377632
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive regimen and risk for de novo malignancies after liver transplantation for alcoholic liver disease.
Dumortier J; Maucort-Boulch D; Poinsot D; Thimonier E; Chambon-Augoyard C; Ducroux E; Vallin M; Walter T; Robinson P; Guillaud O; Boillot O
Clin Res Hepatol Gastroenterol; 2018 Oct; 42(5):427-435. PubMed ID: 29861393
[TBL] [Abstract][Full Text] [Related]
7. De novo malignancies after liver transplantation: a single-center experience.
Hegab B; Khalaf H; Allam N; Azzam A; Al Khail FA; Al-hamoudi W; Kamel Y; Al Bahili H; Al Sofayan M; Al-Sebayel M
Ann Saudi Med; 2012; 32(4):355-8. PubMed ID: 22705604
[TBL] [Abstract][Full Text] [Related]
8. De novo cancer avoidance after renal transplantation: A case-control study on low-dose sirolimus combined with a calcineurin inhibitor.
Chen KH; Lee CY; Wu FL; Yang CY; Yeh CC; Hu RH; Tsai MK
J Formos Med Assoc; 2015 Jun; 114(6):526-31. PubMed ID: 25843527
[TBL] [Abstract][Full Text] [Related]
9. Natural History of Established and De Novo Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis.
Mouchli MA; Singh S; Boardman L; Bruining DH; Lightner AL; Rosen CB; Heimbach JK; Hasan B; Poterucha JJ; Watt KD; Kane SV; Raffals LE; Loftus EV
Inflamm Bowel Dis; 2018 Apr; 24(5):1074-1081. PubMed ID: 29522202
[TBL] [Abstract][Full Text] [Related]
10. Risk factors of de novo malignancies after liver transplantation: a French national study on 11004 adult patients.
Altieri M; Sérée O; Lobbedez T; Segol P; Abergel A; Blaizot X; Boillot O; Boudjema K; Coilly A; Conti F; Chazouillères O; Debette-Gratien M; Dharancy S; Durand F; Duvoux C; Francoz C; Gugenheim J; Hardwigsen J; Houssel-Debry P; Kamar N; Latournerie M; Lebray P; Leroy V; Neau-Cransac M; Pageaux GP; Radenne S; Salamé E; Saliba F; Samuel D; Vanlemmens C; Besch C; Launoy G; Dumortier J
Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101514. PubMed ID: 33714907
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and Prognosis of Colorectal Cancer after Liver or Kidney Transplantation.
Kim M; Kim CW; Hwang S; Kim YH; Lee JL; Yoon YS; Park IJ; Lim SB; Yu CS; Kim JC; Han DJ; Lee SG
World J Surg; 2021 Oct; 45(10):3206-3213. PubMed ID: 34235562
[TBL] [Abstract][Full Text] [Related]
12. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis.
Vera A; Gunson BK; Ussatoff V; Nightingale P; Candinas D; Radley S; Mayer A; Buckels JA; McMaster P; Neuberger J; Mirza DF
Transplantation; 2003 Jun; 75(12):1983-8. PubMed ID: 12829898
[TBL] [Abstract][Full Text] [Related]
13. Impact of calcineurin inhibitor-free immunosuppression on de novo donor-specific antibody formation in liver transplant recipients.
Meszaros M; Dubois V; Congy-Jolivet N; Hamada S; Thevenin C; Faure S; Boillot O; Kamar N; Pageaux GP; Del Bello A; Dumortier J
Liver Int; 2022 May; 42(5):1132-1143. PubMed ID: 35184373
[TBL] [Abstract][Full Text] [Related]
14. The impact of sirolimus on hepatitis C recurrence after liver transplantation.
Asthana S; Toso C; Meeberg G; Bigam DL; Mason A; Shapiro J; Kneteman NM
Can J Gastroenterol; 2011 Jan; 25(1):28-34. PubMed ID: 21258665
[TBL] [Abstract][Full Text] [Related]
15. Incidence and risk factors associated with de novo autoimmune hepatitis after liver transplantation.
Montano-Loza AJ; Vargas-Vorackova F; Ma M; Bain VG; Burak K; Kumar T; Mason AL
Liver Int; 2012 Oct; 32(9):1426-33. PubMed ID: 22712495
[TBL] [Abstract][Full Text] [Related]
16. Clinical Significance of De Novo Malignancy After Liver Transplant: A Single-Center Study.
Kim S; Rovgaliyev B; Lee JM; Lee KW; Hong SK; Cho JH; Yoon KC; Yi NJ; Suh KS
Transplant Proc; 2021; 53(1):200-206. PubMed ID: 32409224
[TBL] [Abstract][Full Text] [Related]
17. Incidence of solid organ cancers after liver transplantation: comparison with regional cancer incidence rates and risk factors.
Carenco C; Faure S; Herrero A; Assenat E; Duny Y; Danan G; Bismuth M; Chanques G; Ursic-Bedoya J; Jaber S; Larrey D; Navarro F; Pageaux GP
Liver Int; 2015 Jun; 35(6):1748-55. PubMed ID: 25488375
[TBL] [Abstract][Full Text] [Related]
18. Transplant oncology: assessment of response and tolerance to systemic chemotherapy for metastatic colorectal cancer after liver transplantation - a retrospective study.
Smedman TM; Guren TK; Line PD; Dueland S
Transpl Int; 2019 Nov; 32(11):1144-1150. PubMed ID: 31209941
[TBL] [Abstract][Full Text] [Related]
19. Neurological complications after liver transplantation as a consequence of immunosuppression: univariate and multivariate analysis of risk factors.
Rompianesi G; Montalti R; Cautero N; De Ruvo N; Stafford A; Bronzoni C; Ballarin R; De Pietri L; Di Benedetto F; Gerunda GE
Transpl Int; 2015 Jul; 28(7):864-9. PubMed ID: 25790037
[TBL] [Abstract][Full Text] [Related]
20. Reducing Immunosuppression in Patients with De Novo Lung Carcinoma after Liver Transplantation Could Significantly Prolong Survival.
Pesthy S; Wegener E; Ossami Saidy RR; Timmermann L; Uluk D; Aydin M; Dziodzio T; Schoening W; Lurje G; Öllinger R; Frost N; Fehrenbach U; Rückert JC; Neudecker J; Pratschke J; Eurich D
Cancers (Basel); 2022 Jun; 14(11):. PubMed ID: 35681728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
